Drug Profile
18F FEMPA
Alternative Names: 18F-FEMPA; F18-FEMPA; FEMPA-18F; FEMPA-F18Latest Information Update: 01 Mar 2019
Price :
$50
*
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Alzheimer's-disease(Diagnosis) in Finland (Parenteral)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Alzheimer's-disease(Diagnosis) in Sweden (Parenteral)
- 13 Nov 2014 18F FEMPA is available for licensing as of 13 Nov 2014. http://piramal.com/piramal-enterprises/piramal-capital